Hong Kong Exchanges and Clearing : ANNOUNCEMENT ON APPLICATION FOR SUSPENSION OF THE REVIEW PROCESS OF THE PROPOSED ISSUE OF A SHARES

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

ANNOUNCEMENT ON APPLICATION FOR SUSPENSION OF THE

REVIEW PROCESS OF THE PROPOSED ISSUE OF A SHARES

This announcement is made by Shanghai Fudan-ZhangjiangBio-Pharmaceutical Co., Ltd.* (the "Company") pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the Company's announcements dated 8 March 2019, 12 March 2019, 26 April 2019, 7 May 2019, 13 May 2019 and 21 June 2019, and circulars dated 12 March 2019, 4 April 2019 and 6 June 2019 containing, among other things, related matters of the proposed initial public issue of A Shares and listing on the Sci-Tech Innovation Board of the Shanghai Stock Exchange (the "Shanghai Stock Exchange") by the Company (the "Proposed Issue of A Shares"). Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the above announcements and circulars.

In accordance with the relevant provisions, the financial statements disclosed in the prospectus of the Company have expired. As the Company is still in the review process of the Proposed Issue of A Shares, it shall report and update the financial statements to cover the first half of 2019 pursuant to the relevant provisions. As such, the Company has submitted to the Shanghai Stock Exchange its application for suspension of the review process of the initial public issue of A shares and listing on the Sci-Tech Innovation Board of the Shanghai Stock Exchange (the "Application"). The Company will promptly submit application for resumption of the review process

- 1 -

to the Shanghai Stock Exchange after the interim results announcement is published. The acceptance of the Application will be published on the website of the Shanghai Stock Exchange at (www.sse.com.cn) in near future.

As the Proposed Issue of A Shares is subject to certain conditions precedent, it may or may not be completed. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the H shares of the Company. Further announcement(s) regarding the details and developments of the Proposed Issue of A Shares will be made by the Company as and when appropriate. This announcement appears for information purposes only and does not constitute an invitation or an offer to acquire, purchase or subscribe for the securities of the Company.

By order of the Board

Wang Hai Bo

Chairman

As at the date on the publication of this announcement, the Board comprises:

Mr. Wang Hai Bo (Executive Director)

Mr. Su Yong (Executive Director)

Mr. Zhao Da Jun (Executive Director)

Mr. Shen Bo (Non-executive Director)

Ms. Yu Xiao Yang (Non-executive Director)

Mr. Zhou Zhong Hui (Independent Non-executive Director)

Mr. Lam Yiu Kin (Independent Non-executive Director)

Mr. Xu Qing (Independent Non-executive Director)

Mr. Yang Chun Bao (Independent Non-executive Director)

Shanghai, the PRC

31 July 2019

* For identification purpose only

- 2 -